Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SB-728mR-T · 1 trial · 1 indication
Number of Participants with Treatment related Adverse Events in subjects who received any portion of the SB-728mR-T infusion
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | - |
| Cohort 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| SB-728mR-T | GENETIC | -SB-728mR-T infusions of 2 equal doses 14 days apart (total of up to 40 billion ZFN modified T-cells) |
| Cyclophosphamide | DRUG | \- IV cyclophosphamide 1 g/m2 two days prior to the first SB-728mR-T infusion |
Inclusion Criteria: * Male or female, 18 years of age or older with documented HIV diagnosis. * Must be willing to comply with study-mandated evaluations; including discontinuation of current antiretroviral therapy during the treatment interruption. * Initiated HAART therapy within (≤) 1 year of HI...
SB-728mR-T is an investigational gene therapy developed by Sangamo Therapeutics for human immunodeficiency virus (HIV). It is a cell-based approach studied in HIV-infected adults who are on HAART (highly active antiretroviral therapy). It has been evaluated in a single completed Phase 1/2 clinical trial.
SB-728mR-T is being studied as a treatment for HIV infection in adults who remain on HAART. The research explores whether repeat doses of the therapy, given after cyclophosphamide conditioning, can be administered to HIV-infected subjects. It is investigational and has not been established as a marketed treatment.
SB-728mR-T is developed by Sangamo Therapeutics, Inc., a biopharmaceutical company whose common stock trades under the ticker SGMOQ. Sangamo is the sponsor of the clinical program evaluating the therapy in HIV.
SB-728mR-T is in Phase 1/2 clinical development. Its only recorded trial, NCT02225665, is a Phase 1/Phase 2 study that has been completed. The therapy is investigational and is not an approved product.
SB-728mR-T has been studied in trial NCT02225665, titled "Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART." The Phase 1/Phase 2 trial enrolled 8 participants in the United States, included both sexes, accepted adults 18 years and older, and is completed.